ONSOLIS

Type: Product
Name: ONSOLIS
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Meda announces termination of JV with Valeant

Swedish speciality pharmaceutical company Meda AB (STO: MEDAA) announced on Monday that it has reached an agreement with Valeant to terminate the companies' joint ventures in Canada, Mexico and Australia in the second quarter of 2014. Meda affiliates ... [Published Individual.com - Apr 08 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 2 reports

BioDelivery Sciences Announces Four BUNAVAIL Abstracts To Be Presented At The 2014 American Society Of Addiction Medicine Annual Conference

RALEIGH, N.C.Four abstracts will be presented highlighting data from the clinical development program, which includes the pivotal bioequivalence study of BUNAVAIL compared to Suboxone tablets and a safety study conducted in 249 subjects undergoing maintenance ... [Published TheStreet.com - Apr 07 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 2 reports

Meda and Valeant Terminates Joint Ventures

GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Meda (STO:MEDAA) has reached an agreement with Valeant to terminate the companies’ joint ventures in Canada, Mexico and Australia in the second quarter of 2014. In all three countries own Meda affiliates ... [Published Business Wire Health News - Apr 07 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

BioDelivery Sciences Announces Commercialization Agreement with Quintiles to Support the Launch of BUNAVAIL in the U.S.

/PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has entered into an agreement with Quintiles to provide a range of services to support the anticipated launch of BUNAVAIL (buprenorphine and naloxone buccal film), ... [Published Fierce CRO - Mar 31 2014]
First reported Mar 27 2014 - Updated Mar 28 2014 - 1 reports

BioDelivery Sciences Announces Commercialization Agreement with Quintiles to Support the Launch of BUNAVAIL in the U.S.

PR NewswireRALEIGH, N.C., March 27, 2014RALEIGH, N.C.BUNAVAIL is currently under review at the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) date of June 7Under terms of the agreement, Quintiles will provide a range ... [Published Digital Journal - Mar 27 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 4 reports

BioDelivery Sciences Provides Business Review and -2-

BDSI's pain franchise consists of three products, two of which utilize the patented BioErodible MucoAdhesive (BEMA) drug delivery technology. ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, E.U. (where it is marketed as BREAKYL) ... [Published Scottrade - Mar 14 2014]

Quotes

- "The agreement is in line with our strategy to focus - beside respiratory- on dermatology, as well as to strengthen our position in emerging markets" said Meda CEO Jorg-Thomas Dierks
...that will be dedicated solely to support the introduction of BUNAVAIL," said David Acheson, Vice President of Sales and Managed Markets for BDSI. "Leading this collaborative effort with Quintiles, BDSI will be in a position to build an experienced and highly committed sales force. Additionally, the added strength of Ashfield Market Access provides us critical access to trade and managed markets by tapping into the resources of individuals with significant experience and long-term relationships with payers. We believe the combined resources of Quintiles and Ashfield Market Access, along with our other partners, our internal commercial experience, and a well differentiated product in BUNAVAIL, will help support a strong introduction."
"From a research and development perspective, we now have two programs in Phase 3 and a third awaiting FDA approval," continued Dr. Sirgo. "The accomplishment of BDSI's key business objectives during the past year is a tribute to the focus and dedication of our employees. In 2014, we are looking forward to an extremely exciting year as we make plans to transition from a development focused organization to a commercial enterprise following our potential approval and subsequent launch of BUNAVAIL. As it relates to the potential launch of BUNAVAIL, we will be providing more details on our launch plan as we approach our June 7"
...Mark A Sirgo, President and Chief Executive Officer. "In 2013, we significantly progressed our product portfolio while adding to it with the licensing of Clonidine Topical Gel. In addition, we have strengthened our management team with several key additions in research and development, finance and commercial organization. Also, with the completion of our $60 million dollar offering in February of this year, we solidified our balance sheet while strengthening our shareholder base."

More Content

All (18) | News (15) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
Meda and Valeant terminate joint ventures [Published Nordic Life Science - Apr 08 2014]
Meda announces termination of JV with Valeant [Published Individual.com - Apr 08 2014]
BioDelivery Sciences Announces Four BUNAVAIL Ab... [Published TheStreet.com - Apr 07 2014]
BioDelivery Sciences Announces Four BUNAVAIL Ab... [Published ADVFN India - Apr 07 2014]
Meda and Valeant Terminate Joint Ventures [Published 4 Traders - Apr 07 2014]
Meda and Valeant terminates joint ventures [Published GlobeNewswire: Advertising News - Apr 07 2014]
Meda and Valeant Terminates Joint Ventures [Published Business Wire Health News - Apr 07 2014]
MEDA : and Valeant terminates joint ventures [Published 4 Traders - Apr 07 2014]
Meda and Valeant terminates joint ventures [Published NASDAQ OMX - Apr 07 2014]
BioDelivery Sciences Announces Commercializatio... [Published Fierce CRO - Mar 31 2014]
BioDelivery Sciences Announces Commercializatio... [Published Digital Journal - Mar 27 2014]
BioDelivery Sciences Announces Commercializatio... [Published Michigan Live - Mar 27 2014]
BioDelivery Sciences Provides Business Review a... [Published Scottrade - Mar 14 2014]
BioDelivery Sciences Provides Business Review A... [Published TheStreet.com - Mar 14 2014]
BioDelivery Sciences Provides Business Review a... [Published ADVFN UK - Mar 14 2014]
BioDelivery Sciences Provides Business Review a... [Published BusinessWeek - Mar 14 2014]
BDSI receives regulatory approval of Onsolis in... [Published PharmaBiz - Jul 31 2013]
BioDelivery Sciences Announces the Hiring of Ad... [Published PR Newswire - Jul 23 2013]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Meda and Valeant Terminates Joint Ventures [Published Business Wire Health News - Apr 07 2014]
GÖTEBORG, Sweden--(BUSINESS WIRE)--Regulatory News: Meda (STO:MEDAA) has reached an agreement with Valeant to terminate the companies’ joint ventures in Canada, Mexico and Australia in the second quarter of 2014. In all three countries own Meda affiliates ...
1

Press Releases

sort by: Date | Relevance
Meda and Valeant terminates joint ventures [Published GlobeNewswire: Advertising News - Apr 07 2014]
BioDelivery Sciences Announces the Hiring of Ad... [Published PR Newswire - Jul 23 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.